文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

来特莫韦与缬更昔洛韦预防高危肾移植受者巨细胞病毒感染:一项随机临床试验

Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项随机、双盲、双模拟、非劣效性3期试验在94个中心纳入601例CMV血清学阴性且接受CMV血清学阳性供肾的成人肾移植受者,比较来特莫韦与缬更昔洛韦预防CMV疾病的效果。结果显示来特莫韦在52周内预防CMV疾病方面非劣效于缬更昔洛韦,且白细胞减少或中性粒细胞减少发生率更低。

要点

  • 来特莫韦在52周内预防CMV疾病非劣效于缬更昔洛韦,两组发生率分别为10.4%与11.8%。
  • 28周内来特莫韦组白细胞减少或中性粒细胞减少发生率为26%,低于缬更昔洛韦组的64%。
  • 来特莫韦组因不良事件停药比例低于缬更昔洛韦组(4.1% vs 13.5%)。

核心结论

  • 在CMV血清学阴性且接受CMV血清学阳性供肾的成人肾移植受者中,来特莫韦在52周内预防CMV疾病方面非劣效于缬更昔洛韦,且白细胞减少或中性粒细胞减少发生率更低,支持其用于该适应症。

研究设计与样本

  • 随机、双盲、双模拟、非劣效性3期试验,2018年5月至2021年4月在94个参与中心纳入成人CMV血清学阴性且接受CMV血清学阳性供肾的肾移植受者,最终随访至2022年4月。
  • 601例参与者按1:1随机分组(按是否接受淋巴细胞清除性诱导免疫抑制分层),589例至少接受一剂研究药物(平均年龄49.6岁;422例[71.6%]男性)。

主要发现

  • 来特莫韦组(n=289)与缬更昔洛韦组(n=297)52周内委员会确认的CMV疾病发生率分别为10.4%与11.8%,分层校正差异为-1.4%(95%CI,-6.5%至3.8%)。
  • 28周内来特莫韦组无参与者发生CMV疾病,缬更昔洛韦组有5例(1.7%)发生CMV疾病。
  • 52周内CMV疾病发病时间两组相当(风险比,0.90[95%CI,0.56-1.47])。
  • 28周内可定量CMV DNA血症来特莫韦组为2.1%,缬更昔洛韦组为8.8%。
  • 在评估疑似CMV疾病或CMV DNA血症的参与者中,来特莫韦组无(0/52)出现耐药相关替换,缬更昔洛韦组有12.1%(8/66)出现耐药相关替换。

关键数值与推荐

  • 主要结局为移植后52周内经独立盲法裁定委员会确认的CMV疾病,预设非劣效性界值为10%。
  • 28周内白细胞减少或中性粒细胞减少发生率来特莫韦组为26%,缬更昔洛韦组为64%,差异为-37.9%(95%CI,-45.1%至-30.3%;P < .001)。
  • 来特莫韦组因不良事件停止预防用药的比例为4.1%,缬更昔洛韦组为13.5%;因药物相关不良事件停药的比例分别为2.7%与8.8%。

临床怎么用

  • 原文结论支持来特莫韦用于CMV血清学阴性且接受CMV血清学阳性供肾的成人肾移植受者的CMV疾病预防。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Valganciclovir for 200 days is standard care for cytomegalovirus (CMV) prophylaxis in high-risk CMV-seronegative kidney transplant recipients who receive an organ from a CMV-seropositive donor, but its use is limited by myelosuppression. OBJECTIVE: To compare the efficacy and safety of letermovir with valganciclovir for prevention of CMV disease in CMV-seronegative kidney transplant recipients who receive an organ from a CMV-seropositive donor. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-masked, double-dummy, noninferiority, phase 3 trial in adult CMV-seronegative kidney transplant recipients who received an organ from a CMV-seropositive donor at 94 participating sites between May 2018 and April 2021 (final follow-up in April 2022). INTERVENTIONS: Participants were randomized in a 1:1 ratio (stratified by receipt of lymphocyte-depleting induction immunosuppression) to receive letermovir, 480 mg, orally daily (with acyclovir) or valganciclovir, 900 mg, orally daily (adjusted for kidney function) for up to 200 days after transplant, with matching placebos. MAIN OUTCOMES AND MEASURES: The primary outcome was CMV disease, confirmed by an independent masked adjudication committee, through posttransplant week 52 (prespecified noninferiority margin, 10%). CMV disease through week 28 and time to onset of CMV disease through week 52 were secondary outcomes. Exploratory outcomes included quantifiable CMV DNAemia and resistance. The rate of leukopenia or neutropenia through week 28 was a prespecified safety outcome. RESULTS: Among 601 participants randomized, 589 received at least 1 dose of the study drug (mean age, 49.6 years; 422 [71.6%] men). Letermovir (n = 289) was noninferior to valganciclovir (n = 297) for prevention of CMV disease through week 52 (10.4% vs 11.8% of participants with committee-confirmed CMV disease; stratum-adjusted difference -1.4% [95% CI, -6.5% to 3.8%]). No participants who received letermovir vs 5 participants (1.7%) who received valganciclovir developed CMV disease through week 28. Time to onset of CMV disease was comparable between the groups (hazard ratio, 0.90 [95% CI, 0.56-1.47]). Quantifiable CMV DNAemia was detected in 2.1% of participants in the letermovir group vs 8.8% in the valganciclovir group by week 28. Of participants evaluated for suspected CMV disease or CMV DNAemia, none (0/52) who received letermovir and 12.1% (8/66) who received valganciclovir had resistance-associated substitutions. The rate of leukopenia or neutropenia through week 28 was lower with letermovir vs valganciclovir (26% vs 64%; difference, -37.9% [95% CI, -45.1% to -30.3%]; P < .001). Fewer participants in the letermovir group than the valganciclovir group discontinued prophylaxis due to adverse events (4.1% vs 13.5%) or drug-related adverse events (2.7% vs 8.8%). CONCLUSION AND RELEVANCE: Among adult CMV-seronegative kidney transplant recipients who received an organ from a CMV-seropositive donor, letermovir was noninferior to valganciclovir for prophylaxis of CMV disease over 52 weeks, with lower rates of leukopenia or neutropenia, supporting its use for this indication. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03443869; EudraCT: 2017-001055-30.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Limaye AP, Budde K, Humar A, et al. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA. 2023. PMID: 37279999. doi:10.1001/jama.2023.9106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。